Hemispherx To Supply Ampligen for Pancreatic Cancer Patients in Canada Under Special Access Program

ORLANDO, Fla., Feb. 26, 2018  -- Hemispherx Biopharma, Inc. (NYSE American:HEB) said it is expanding its partnership with myTomorrows to supply Ampligen® for pancreatic cancer patients in Canada under a Special Access Program (SAP).
 
Amsterdam-based myTomorrows, an international leader in providing physicians access to experimental medicines, is conducting a similar program with Ampligen in Europe, where it is called an EAP, or Early Access Program. 
 
In clinical trials in a variety of indications, approximately 100,000 doses of the experimental drug Ampligen have been administered, IV or intranasally, resulting in one of the most comprehensive safety profiles of a Toll-like receptor agonist. Toll-like receptors (TLRs) are a class of proteins that play a key role in activating the innate immune system.
Read more: Hemispherx Biopharma ( HEB )

Acasti Pharma Announces Development and Commercialization Discussions Progressing with a Leading China Pharmaceutical Partner

LAVAL, QUÉBEC--(Nov. 20, 2017) - Acasti Pharma Inc. (NASDAQ:ACST)(TSX VENTURE:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the company recently entered into a non-binding term sheet with a leading China-based pharmaceutical company. Completion of the transaction is subject to further negotiation and execution of a definitive agreement, which once signed would grant an exclusive license to the Chinese pharmaceutical company to commercialize CaPre in certain Asian countries, including China. With the high prevalence of hypertriglyceridemia in Asia, this potential partnership presents a significant opportunity for Acasti and CaPre.
Read more: Acasti Pharma Inc ( ACST )

Apricus Biosciences Announces FDA Acknowledgement of Vitaros ™ Class 2 NDA Resubmission

SAN DIEGO, Aug. 31, 2017 -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S. Food and Drug Administration (“FDA”) has acknowledged receipt of its recently resubmitted New Drug Application (“NDA”) for Vitaros™ (alprostadil, DDAIP.HCl) and considers it a complete, class 2 response to Apricus’ 2008 action letter.  The PDUFA (Prescription Drug User Fee Act) goal date for completion of the FDA’s review of the Vitaros NDA is set for February 17, 2018, which is the standard six month review period for NDA resubmissions.
 
Vitaros is a novel, on-demand topical cream for the treatment of erectile dysfunction (“ED”) and a new potential entrant into the U.S. ED treatment market. Vitaros has been approved in Canada, Mexico, and certain countries in Europe, Latin America and the Middle East, and the product is being commercialized by Ferring International Center S.A. and its licensees throughout Europe and in the Middle East.
Read more: Apricus Biosciences Inc ( APRI )

XOMA Announces Transformational License Agreements for Gevokizumab and its IL-1 Beta Intellectual Property Portfolio

$31 million in upfront payments including $5 million equity investment
50 percent reduction in XOMA’s outstanding debt through repayment of its €12 million obligation to Les Laboratoires Servier
Significant potential milestone payments plus tiered royalties on sales of gevokizumab
Maturity date on XOMA’s debt to Novartis extended by two years
 
BERKELEY, Calif., Aug. 25, 2017 -- XOMA Corporation (Nasdaq: XOMA), a pioneer in the discovery and development of therapeutic antibodies, today announced it has licensed the global commercial rights to gevokizumab, a novel anti-IL-1 beta allosteric monoclonal antibody, to Novartis. In a separate agreement, XOMA has granted Novartis a license to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment of cardiovascular disease.
Read more: XOMA Corporation ( XOMA )

PetMed Express D/B/A 1-800-PetMeds Announces Record First Quarter Financial Results

First Quarter Net Income Increased 41%
First Quarter New Order Sales Increased 14%
First Quarter Online Sales Increased 12%
 
DELRAY BEACH, Fla., July 24, 2017 -- PetMed Express, Inc. (NASDAQ:PETS) today announced its financial results for the quarter ended June 30, 2017.  Net income was $9.3 million, or $0.45 diluted per share, for the quarter ended June 30, 2017, compared to net income of $6.6 million, or $0.32 diluted per share, for the quarter ended June 30, 2016, a 41% increase to net income.  Net sales for the quarter ended June 30, 2017 were $79.7 million, compared to $72.5 million for the quarter ended June 30, 2016, an increase of 10%.  New order sales increased 14%, to $15.2 million for the quarter ended June 30, 2017, compared to $13.3 million for the same quarter in the prior year.  The Company’s online sales for the quarter ended June 30, 2017 were approximately 84% of all sales compared to 82% for the same quarter the prior year, with online sales increasing 12%. 
Read more: PetMed Express ( PETS )

Videos / Webinars

View all videos